Clinical trial NCT04560309: Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF
Official title: Role of Glutamine as Myocardial Protector in Elective On-Pump Coronary Artery Bypass Graft Surgery With Low Ejection Fraction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Coronary Artery Bypass
Cardiopulmonary Bypass
Coronary Artery Disease
Keywords: Glutamine
Myocardial protection
Coronary artery bypass grafting
Cardiopulmonary bypass
Low ejection fraction
Myocardial injury
Lead sponsor: National Cardiovascular Center Harapan Kita Hospital Indonesia
Sponsor class: OTHER
First posted: 2020-09-23
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Coronary artery disease has the highest mortality rate worldwide and coronary artery bypass grafting (CABG) is the most common cardiac surgery performed in patients with coronary artery disease to revascularize the heart. Despite of improvement in operation techniques, cardioplegia, cardiopulmonary bypass (CPB), myocardial injury related to on-pump CABG is still prominent. In patient with low ejection fraction undergone on-pump CABG, myocardial injury is related to worse outcome and prognosis during peri-operative and post-operative period. On-pump CABG patients with low ejection fraction has increased (up to four times higher) post-operative in hospital mortality rate compared to patient with normal ejection fraction. Administration of intravenous glutamine had been documented in reducing myocardial damage during cardiac surgery and previous studies indicated that glutamine can protect against myocardial injury by various mechanism during ischemia and reperfusion. The purpose of this study to determine whether intravenous glutamine could prevent the decline of plasma glutamine level, reduce myocardial damage, improve hemodynamic profile, and reduce morbidity of on-pump CABG in patients with low ejection fraction.

Detailed description: The study was a double-blind randomized controlled trial to assess the role of glutamine as a myocardial protection during coronary artery bypass grafting under cardiopulmonary bypass in patients with left ventricle ejection fraction of 31-50%. This study was approved by Institutional Review Board of National Cardiovascular Center Harapan Kita and informed consent was obtained before randomization for patient eligible for this study. Allocation of participant to the treatment group was done by block randomization by staff who was not involved in the study. The intervention drug was prepared by pharmacist who also was not involved in the study. Glutamine solution was supplied as L-alanyl-L-glutamine dipeptide (Dipeptiven, 200 mg/mL, Fresenius Kabi, Bad Homburg, Germany) and was prepared to contain 0.5gr/kgbw glutamine diluted in NaCl 0.9% to a final volume of 500 mL. Placebo was supplied as 500 ml of NaCl 0.9%, prepared in similar fashion and packaging as glutamine solution. Principal investigator, care provider, outcome assessor, and participant were blinded to the assigned group until after the end of the study.

Baseline participant characteristics were collected before the intervention included age, sex, body weight, body height, body mass index, and documented pre-operative left ventricle ejection fraction. Coronary artery bypass grafting and cardiopulmonary bypass was done in concordance to standard operating procedure in National Cardiovascular Center Harapan Kita, followed by transit time flow meter measurement to ensure quality of the graft. Modifying factor of the study, the investigators measured duration of surgery, duration of cardiopulmonary bypass, and duration of aortic cross clamp.

The primary outcome of the study was plasma troponin I level. The investigators anticipated plasma troponin I level difference of 20% with standard deviation of 0.04 ng/mL, and for statistical power of 80% and level of significance of 0.05, the required sample size was 24.5 participants per group. As anticipation for participant drop out, the investigators planned to recruit a total of 60 participants.

Eligibility criteria: Inclusion Criteria:

* Patients with coronary heart disease indicated for elective coronary artery bypass grafting under cardiopulmonary bypass
* Patients with left ventricle ejection fraction 31% -50% confirmed by echocardiography or radio nuclear study.
* Patients age ≥18 years
* Never had heart surgery before
* Agree to participate in the study and signed informed consent

Exclusion Criteria:

* Emergency coronary artery grafting bypass
* Having additional procedures other than coronary artery bypass grafting
* History of myocardial infarction with onset less than 3 months
* Patients with serum creatinine level more than 2 g/dL
* Patients with ALT/AST levels more than 1.5 times the upper limit of normal value
* Required to use intra-aortic balloon pump pre-operatively
* History of stroke with onset less than 3 months
* History of pre-operative atrial fibrillation
* History of heart conduction problem and/or using a pacemaker
* Patients with HIV
* Contraindications to pulmonary artery catheter insertion

Drop out Criteria

* Experiencing stroke after surgery
* Experiencing surgery related complication (haemorrhage) requiring re operation
* Requiring continuous veno-venous hemofiltration or haemodialysis after surgery
* Delayed sternal closure
* Aortic cross clamp duration more than 120 minutes and/or cardiopulmonary bypass time more than 180 minutes

Primary outcomes:
measure: Plasma Troponin I at Baseline
timeFrame: Before induction to anesthesia
measure: Plasma Troponin I at 5 Minute After Cardiopulmonary Bypass
timeFrame: 5 minute after cardiopulmonary bypass
measure: Plasma Troponin I at 6 Hour After Cardiopulmonary Bypass
timeFrame: 6 hour after cardiopulmonary bypass
measure: Plasma Troponin I at 24 Hour After Cardiopulmonary Bypass
timeFrame: 24 hour after cardiopulmonary bypass
measure: Plasma Troponin I at 48 Hour After Cardiopulmonary Bypass
timeFrame: 48 hour after cardiopulmonary bypass
measure: Plasma Glutamine at Baseline
timeFrame: Before induction to anesthesia
measure: Plasma Glutamine at 24 Hour After Cardiopulmonary Bypass
timeFrame: 24 hour after cardiopulmonary bypass
Secondary outcomes:
measure: Right Atrial Appendage Alpha-ketoglutarate
timeFrame: 5 minute after cardiopulmonary bypass
measure: Right Atrial Appendage Myocardial Injury Score
timeFrame: 5 minute after cardiopulmonary bypass
measure: Right Atrial Appendage Apoptosis Index
timeFrame: 5 minute after cardiopulmonary bypass
measure: Anti Cardiac Troponin I Expression
timeFrame: 5 minute after cardiopulmonary bypass
measure: Ejection Fraction
timeFrame: Immediately after induction of anesthesia
measure: Ejection Fraction
timeFrame: 5 minutes after cardiopulmonary bypass
measure: Cardiac Index
timeFrame: Immediately after induction of anesthesia, 5 minute, 2 hour, 6 hour, 24 hour after cardiopulmonary bypass
measure: Plasma Lactate Before Induction to Anesthesia
timeFrame: Before induction to anesthesia
measure: Plasma Lactate 5 Minute After Cardiopulmonary Bypass
timeFrame: 5 minute after cardiopulmonary bypass
measure: Plasma Lactate 6 Hours After Cardiopulmonary Bypass
timeFrame: 6 hours after cardiopulmonary bypass
measure: Plasma Lactate 24 Hours After Cardiopulmonary Bypass
timeFrame: 24 hours after cardiopulmonary bypass
measure: Plasma Lactate 48 Hours After Cardiopulmonary Bypass
timeFrame: 48 hours after cardiopulmonary bypass
measure: Intensive Care Unit Ventilation Time
timeFrame: 28 days (or until hospital discharge)
measure: Intensive Care Unit Length of Stay
timeFrame: 28 days (or until hospital discharge)
measure: Vasoactive Inotropic Score
timeFrame: 28 days (or until hospital discharge)
Other outcomes:
measure: Coronary Graft
timeFrame: Intraoperative
measure: Total Surgical Procedure Time
timeFrame: Intraoperative
measure: Cardiopulmonary Bypass Time
timeFrame: Intraoperative
measure: Aortic Cross-clamping Time
timeFrame: Intraoperative
Locations:
city: Jakarta
country: Indonesia
facility: National Cardiovascular Center Harapan Kita Hospital Indonesia
Study officials:
affiliation: National Cardiovascular Center Harapan Kita Indonesia
name: I Made Adi Parmana
role: PRINCIPAL_INVESTIGATOR
References: